← Back to Search

Diagnostic Imaging for Coronary Heart Disease (SWAN Trial)

N/A
Waitlist Available
Led By Harmony Reynolds, M.D.
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Women with positive cardiac markers and/or ST elevation scheduled for angiography
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within one week of enrollment
Awards & highlights

SWAN Trial Summary

This trial will help doctors understand why some women have heart attacks even when they don't have any major blockages in their heart arteries.

Who is the study for?
This trial is for women who have had a heart attack or unstable angina and are scheduled for an angiography, but do not have major blockages in their heart arteries. Women with previous obstructive coronary artery disease, those who can't undergo IVUS or MRI procedures, or those using vasospastic agents cannot participate.Check my eligibility
What is being tested?
The study uses intravascular ultrasound (IVUS) to take pictures of the inside of arteries and magnetic resonance imaging (MRI) to assess blood flow and damage in the heart. It aims to understand why some women experience heart attacks despite having no significant blockage in their arteries.See study design
What are the potential side effects?
While this study does not involve drugs that could cause typical medication side effects, IVUS and MRI are generally safe but may include risks such as discomfort during the procedure, allergic reactions to contrast materials used, or complications from lying still during MRI.

SWAN Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman with heart issues scheduled for a heart vessel check.

SWAN Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within one week of enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and within one week of enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
IVUS and MRI findings

SWAN Trial Design

1Treatment groups
Experimental Treatment
Group I: WomenExperimental Treatment2 Interventions
IVUS and MRI performed in women with no obstructive CAD at angiography
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI
2009
Completed Phase 2
~1370
Intravascular ultrasound
2007
N/A
~160

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,368 Previous Clinical Trials
839,676 Total Patients Enrolled
1 Trials studying Acute Coronary Syndrome
714 Patients Enrolled for Acute Coronary Syndrome
Doris Duke Charitable FoundationOTHER
61 Previous Clinical Trials
260,075 Total Patients Enrolled
Harmony Reynolds, M.D.Principal InvestigatorNYU Langone Health

Media Library

Intravascular ultrasound Clinical Trial Eligibility Overview. Trial Name: NCT00798122 — N/A
Acute Coronary Syndrome Research Study Groups: Women
Acute Coronary Syndrome Clinical Trial 2023: Intravascular ultrasound Highlights & Side Effects. Trial Name: NCT00798122 — N/A
Intravascular ultrasound 2023 Treatment Timeline for Medical Study. Trial Name: NCT00798122 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there availability for participants in this research?

"This clinical trial, initially posted on March 1st 2006 and last updated October 31st 2022, is no longer recruiting participants. However, according to clinicaltrials.gov there are currently 1986 other medical trials actively enrolling patients."

Answered by AI
~3 spots leftby Apr 2025